Replies to post #368436 on Amarin Corp Plc (AMRN)

[Number sleven]

Marjac, Do you still expect to see an amended claim filed against Hikma this week?
Sleven,

[ziploc_1]

Marjac...potential Amarin arguments against these Healthnet's claims...

Healthnet claim 1."a Declaration that they(Healthnet) are not infringing"...
Prior authorization requests to Docs show that Healthnet has been definitely infringing on Amarin's CVD patents.

Healthnet claim 2."even if they(Healthnet) are infringing, a Declaration that the patents are invalid"...
Judge Du already found the R-IT patents for CVD to be valid,i.e. in the Hickma vs. Amarin patent suit.

[Pharmacydude]

Marjac
As I previously posted, estrogen is known to reduce ApoB and therefore the cropped ApoB table shows an expected reduction in ApoB levels in both the placebo (estrogen only) and the estrogen/EPA groups. Since it would be necessary to show that POSA at that time would know that, I have linked a study showing these results from 1997 just in case the generics argue that it wasn’t known at the time of the patent being issued.

Effect of Estrogen on Very Low Density Lipoprotein and Low Density Lipoprotein Subclass Metabolism in Postmenopausal Women

https://academic.oup.com/jcem/article/82/12/3955/2865931


“These metabolic changes reduced light LDL cholesterol and apoB concentrations by 26% (P = 0.005) and 19% (P = 0.03), respectively.”